ACROBiosystems Launches AI-Driven Drug Discovery Support Platform

The integration of artificial intelligence into drug discovery has enabled rapid generation of candidate molecules, yet experimental validation remains a bottleneck for many research teams. By launching the CHO-Direct service, ACROBiosystems offers a streamlined pathway that utilizes optimized mammalian cell systems to translate sequence submissions into structured affinity data. This approach allows pharmaceutical and biotech companies to evaluate computational predictions with greater speed, focusing resources on the most promising candidates.

Beyond basic affinity testing, the broader ACRO AIx infrastructure supports a multidimensional validation framework. Researchers can access a vast portfolio of target proteins and membrane protein targets, alongside high-throughput kits for functional pathway inhibition screening. The system extends into cellular and organoid models, including human-derived cardiac, brain, and kidney platforms, which provide higher biological relevance during the early R&D phase.

ACRO AIx also addresses the need for workflow connectivity through standardized tool sets and open application interfaces. By offering options such as the CHO-Direct Tool Set and cell-free expression kits, the company enables teams to reproduce experimental modules within their own laboratories. Crucially, ACROBiosystems maintains an open-infrastructure model; it does not develop its own drug pipeline, ensuring that customers retain full ownership of their intellectual property and research data. To support global access, the company has simultaneously introduced the GlobalLifeShip supply chain platform, facilitating international logistics and warehousing for its partners.